Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Alder BioPharmaceuticals® Appoints Carlos Campoy Chief Financial Officer | ||
By: Nasdaq / GlobeNewswire - 11 Dec 2018 | Back to overview list |
|
BOTHELL, Wash., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced the appointment of Carlos Campoy as Chief Financial Officer, effective December 12, 2018. Mr. Campoy brings nearly 30 years of financial leadership and expertise across global publicly-traded companies, including over 20 years in the biopharmaceutical and healthcare sectors. Mr. Campoy served as Vice President of Finance, International at Allergan plc where he had financial responsibility for $3B in sales driving significant growth across all product divisions which included Neurosciences and BOTOX®. In this role, he led the strategic, operational, and financial decision-making for the region and successfully designed and implemented new financial processes and organizational structure. Prior to joining Allergan, Mr. Campoy had an 18-year tenure at Eli Lilly and Company, where he held a number of senior financial leadership positions including Chief Financial Officer, Eli Lilly Japan K.K., with financial responsibility for $2B in sales. He also served as U.S. Senior Director of Finance and Chief Financial Officer for the U.S. Specialty sales and marketing team with responsibility for planning, forecasting and reporting, financial controls, managed care, pricing, contracting, sales analytics, and distribution. He most recently served as Partner of Think Forwards, a financial consulting firm focused on providing innovative solutions and transformational initiatives to drive growth. “Carlos is a highly experienced, performance-driven CFO with deep financial and operational expertise across competitive markets,” said Bob Azelby, President and Chief Executive Officer. “His contributions to our management team will be highly valuable as we continue to build our commercial infrastructure in anticipation of the potential launch of eptinezumab in the first quarter of 2020.” “I am excited to join Alder during this important time, as the Company enters its next stage of growth,” said Mr. Campoy. “I look forward to leading Alder’s financial function and working closely with Bob and the leadership team as the Company continues to build out its processes and infrastructure to prepare for the successful commercialization of eptinezumab.” Mr. Campoy is a Certified Management Accountant (CMA). He received an MBA in Finance and Decision Information Systems from Indiana University and a BS in Management from Faculdade C.C. Administracao de Tupa, in São Paulo, Brazil. He previously served on the Board of TP Orthodontics from 2006 to 2010. About Alder BioPharmaceuticals, Inc. Forward-Looking Statements Investor Relations Contact: Michael Schaffzin Media Contact: Ashley Cadle
|
||
|
||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |